Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study

The Lancet Haematology

Volumn 4, Issue 4, 2017, Pages e157-e164

  Bendapudi, Pavan K ^a,g   Hurwitz, Shelley ^b,g   Fry, Ashley ^c   Marques, Marisa B ^d   Waldo, Stephen W ^e   Li, Ang ^a,g   Sun, Lova ^a,g   Upadhyay, Vivek ^a,g   Hamdan, Ayad ^f,g   Brunner, Andrew M ^a,g   Gansner, John M ^b,g   Viswanathan, Srinivas ^a,g   Kaufman, Richard M ^b,g   Uhl, Lynne ^f,g   Stowell, Christopher P ^a,g   Dzik, Walter H ^a,g   Makar, Robert S ^a,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Heerskink School of Medicine   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; HAPTOGLOBIN; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PLASMIC SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; BIOLOGICAL MODEL; COHORT ANALYSIS; DEFICIENCY; ENZYMOLOGY; MIDDLE AGED;

ADAMTS13 PROTEIN; ADULT; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 85014108297     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(17)30026-1     Document Type: Article

References (27)

1. 1 Furlan, M, Robles, R, Galbusera, M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998), 1578–1584.
2. 2 Tsai, HM, Lian, EC, Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998), 1585–1594.
3. 3 Hassan, S, Westwood, JP, Ellis, D, et al. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br J Haematol 171 (2015), 830–835.
4. 4 Williams, LA, Marques, MB, Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs). Am J Clin Pathol 145 (2016), 158–165.
5. 5 Bendapudi, PK, Makar, RS, An algorithmic approach to the diagnosis and management of the thrombotic microangiopathies. Am J Clin Pathol 145 (2016), 152–154.
6. 6 Rock, GA, Shumak, KH, Buskard, NA, et al., for the Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325 (1991), 393–397.
7. 7 Connell, NT, Cheves, T, Sweeney, JD, Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. Transfusion 56 (2016), 354–359.
8. 8 Souto Filho, JT, de Barros, PV, da Silva, AM, Barbosa, FA, Ribas, GF, Thrombotic thrombocytopenic purpura associated with mixed connective tissue disease: a case report. Case Rep Med, 2011, 2011, 953890.
9. 9 Novitzky, N, Thomson, J, Abrahams, L, du Toit, C, McDonald, A, Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol 128 (2005), 373–379.
10. 10 Bendapudi, PK, Li, A, Hamdan, A, et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol 171 (2015), 836–844.
11. 11 Meyer, SC, Sulzer, I, Lammle, B, Kremer Hovinga, JA, Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 5 (2007), 866–867.
12. 12 Gerritsen, HE, Turecek, PL, Schwarz, HP, Lammle, B, Furlan, M, Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82 (1999), 1386–1389.
13. 13 Kokame, K, Matsumoto, M, Fujimura, Y, Miyata, T, VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103 (2004), 607–612.
14. 14 Kokame, K, Nobe, Y, Kokubo, Y, Okayama, A, Miyata, T, FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129 (2005), 93–100.
15. 15 Shah, N, Rutherford, C, Matevosyan, K, Shen, YM, Sarode, R, Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163 (2013), 514–519.
16. 16 Li, A, Makar, RS, Hurwitz, S, et al. Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study. Transfusion 56 (2016), 2069–2077.
17. 17 Brier, GW, Verification of forecasts expressed in terms of probability. Mon Weather Rev 78 (1950), 1–3.
18. 18 Bradley, AA, Schwartz, SS, Hashino, T, Sampling uncertainty and confidence intervals for the Brier score and Brier skill score. Weather Forecast 23 (2008), 992–1006.
19. 19 Redelmeier, DA, Bloch, DA, Hickam, DH, Assessing predictive accuracy: how to compare Brier scores. J Clin Epidemiol 44 (1991), 1141–1146.
20. 20 Pencina, MJ, D'Agostino, RB Sr, Demler, OV, Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med 31 (2012), 101–113.
21. 21 Waldo, SW, Chang, L, Strom, JB, O'Brien, C, Pomerantsev, E, Yeh, RW, Predicting the presence of an acute coronary lesion among patients resuscitated from cardiac arrest. Circ Cardiovasc Interv, 8, 2015, e002198.
22. 22 Coppo, P, Schwarzinger, M, Buffet, M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One, 5, 2010, e10208.
23. 23 DeLong, ER, DeLong, DM, Clarke-Pearson, DL, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988), 837–845.
24. 24 Bentley, MJ, Lehman, CM, Blaylock, RC, Wilson, AR, Rodgers, GM, The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion 50 (2010), 1654–1664.
25. 25 Vesely, SK, George, JN, Lammle, B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102 (2003), 60–68.
26. 26 Scully, M, Yarranton, H, Liesner, R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142 (2008), 819–826.
27. 27 Kremer Hovinga, JA, Vesely, SK, Terrell, DR, Lammle, B, George, JN, Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115 (2010), 1500–1511.